control in patients with mild asthma. A goal of clinical investigation should be to provide new information and a firm scientific rationale from which to devise the next set of guidelines.

Stephen P. Peters, M.D., Ph.D.
Wake Forest University
Winston-Salem, NC 27157

Mario Castro, M.D.
Washington University
St. Louis, MO 63110-1093

Janet T. Holbrook, M.P.H., Ph.D.
Johns Hopkins University
Baltimore, MD 21205
jholbroo@jhsph.edu

TO THE EDITOR: In the study of rescue use of beclomethasone and albuterol in a single inhaler for mild asthma reported by Papi et al. (May 17 issue), the morning peak expiratory flow rate (based on peak-flow diaries) was the primary end point, although there is enough reason to doubt its clinical relevance, its validity, and its physiological meaning in a disease that predominantly affects smaller airways. The peak expiratory flow rate reflects mainly central-airway mechanics and is insensitive for the monitoring of peripheral-airway patency. Only because no Bonferroni correction was used, the morning peak expiratory flow rate — but not the evening peak expiratory flow rate or variability in peak expiratory flow rate — was marginally significantly different (P = 0.04) between the as-needed combination group and the as-needed albuterol group, whereas the secondary end points of forced expiratory volume in 1 second and forced vital capacity (percent of the predicted value) proved to be much more sensitive in detecting a treatment effect. A similar situation was reported previously, and the study by Papi et al. once again illustrates that measures of peak expiratory flow rate are insensitive and therefore, in my opinion, do not reflect the disease adequately.

Peter J.F.M. Merkus, M.D., Ph.D.
Sophia Children’s Hospital
3000CB Rotterdam, the Netherlands
p.j.f.m.merkus@erasmusmc.nl


THE AUTHORS REPLY: Merkus is concerned that the use of the morning peak expiratory flow rate, based on peak-flow diaries, may be misleading because it is insensitive and may not reflect small-airway abnormalities. Measurement of the peak expiratory flow rate is still recommended in international guidelines for monitoring asthma. It is incorrect to state that the peak expiratory flow rate did not differ significantly between the groups in our study, since the morning peak expiratory flow rate was indeed sensitive enough to detect significant differences, in direct comparisons of the experimental treatment (as-needed use of combination albuterol–beclomethasone and regular use of beclomethasone) and the control treatment (as-needed use of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. [Erratum, Chest 2006;129:1393.]

Mario Castro, M.D.
Washington University
St. Louis, MO 63110-1093

Stephen P. Peters, M.D., Ph.D.
Wake Forest University
Winston-Salem, NC 27157


THE AUTHORS REPLY: The conclusions by Papi and colleagues with respect to the effectiveness and medication-sparing capacity of inhaled beclomethasone–albuterol as intermittent therapy for mild persistent asthma are based on their study of adults. The application of this method to children requires proof of principle. Lung growth, which affects treatment outcomes over time in children, could obviously not be accounted for in their study.

Luigi Terracciano, M.D.
Alessandro Fiocchi, M.D.
Gabriel R. Bouygue, M.Sc.
University of Milan Medical School
20129 Milan, Italy
allerg@tin.it

TO THE EDITOR: The conclusions by Papi and colleagues with respect to the effectiveness and medication-sparing capacity of inhaled beclomethasone–albuterol as intermittent therapy for mild persistent asthma are based on their study of adults. The application of this method to children requires proof of principle. Lung growth, which affects treatment outcomes over time in children, could obviously not be accounted for in their study.

Mario Castro, M.D.
Washington University
St. Louis, MO 63110-1093

Stephen P. Peters, M.D., Ph.D.
Wake Forest University
Winston-Salem, NC 27157


THE AUTHORS REPLY: The conclusions by Papi and colleagues with respect to the effectiveness and medication-sparing capacity of inhaled beclomethasone–albuterol as intermittent therapy for mild persistent asthma are based on their study of adults. The application of this method to children requires proof of principle. Lung growth, which affects treatment outcomes over time in children, could obviously not be accounted for in their study.

Luigi Terracciano, M.D.
Alessandro Fiocchi, M.D.
Gabriel R. Bouygue, M.Sc.
University of Milan Medical School
20129 Milan, Italy
allerg@tin.it

TO THE EDITOR: The conclusions by Papi and colleagues with respect to the effectiveness and medication-sparing capacity of inhaled beclomethasone–albuterol as intermittent therapy for mild persistent asthma are based on their study of adults. The application of this method to children requires proof of principle. Lung growth, which affects treatment outcomes over time in children, could obviously not be accounted for in their study.

Luigi Terracciano, M.D.
Alessandro Fiocchi, M.D.
Gabriel R. Bouygue, M.Sc.
University of Milan Medical School
20129 Milan, Italy
allerg@tin.it

THE AUTHORS REPLY: The conclusions by Papi and colleagues with respect to the effectiveness and medication-sparing capacity of inhaled beclomethasone–albuterol as intermittent therapy for mild persistent asthma are based on their study of adults. The application of this method to children requires proof of principle. Lung growth, which affects treatment outcomes over time in children, could obviously not be accounted for in their study.

Luigi Terracciano, M.D.
Alessandro Fiocchi, M.D.
Gabriel R. Bouygue, M.Sc.
University of Milan Medical School
20129 Milan, Italy
allerg@tin.it
use of albuterol). To the best of our knowledge, there is no single test of airway function that reflects the prevalent site of airflow obstruction in asthma, and there is no evidence from clinical trials that physiological measures that are thought to reflect peripheral Airways correlate better with respiratory symptoms than other tests of airway function. We agree that since the objective of asthma treatment is to ensure clinical control, it would be of value to design trials that involve patient-centered outcomes.

We also agree with Terracciano and colleagues that treatments for asthma should be tested in children with mild asthma. A randomized clinical trial sponsored by the National Heart, Lung, and Blood Institute is currently under way to address this important issue (the Childhood Asthma Research and Education [CARE] Network Trial — Treating Children to Prevent Exacerbations of Asthma [TREXA]; ClinicalTrials.gov number, NCT00394329).

Alberto Papi, M.D.
University of Ferrara
44100 Ferrara, Italy

Gabriele Nicolini, Pharm.D.
Chiesi Farmaceutici
43100 Parma, Italy

Leonardo M. Fabbri, M.D.
University of Modena and Reggio Emilia
41100 Modena, Italy


Robert M. Sade, M.D.
American Medical Association
Chicago, IL 60610


TO THE EDITOR: Voluntary guidelines issued by the pharmaceutical industry in 2002 addressing interactions with health professionals include a ban on direct payments to physicians for attendance at CME or other conference events. According to the guidelines, any industry support for conferences or courses should be provided indirectly through event organizers. Despite this guideline, Campbell et al. state that 35% of the physicians in their survey reported receiving reimbursement for “costs of travel, time, meals, lodging, or other personal expenses for attending meetings,” “free